Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 1,171

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)

Open access
Cardoso, F., Senkus, E., Costa, A., Papadopoulos, E., Aapro, M., André, F., Harbeck, N., Aguilar Lopez, B., Barrios, C.H., Bergh, J., Biganzoli, L., Boers-Doets, C.B., Cardoso, M.J., Carey, L.A., Cortés, J., Curigliano, G., Diéras, V., El Saghir, N.S., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Johnston, S.R.D., Kaufman, B., Koppikar, S., Krop, I.E., Mayer, M., Nakigudde, G., Offersen, B.V., Ohno, S., Pagani, O., Paluch-Shimon, S., Penault-Llorca, F., Prat, A., Rugo, H.S., Sledge, G.W., Spence, D., Thomssen, C., Vorobiof, D.A., Xu, B., Norton, L., Winer, E.P.·2018·Annals of Oncology
DOI 10.1093/annonc/mdy192
Open this paper in CoChat — free account

Abstract

Advanced Breast Cancer (ABC) comprises both locally advanced breast cancer (LABC) and metastatic breast cancer (MBC) [1]. Although treatable, MBC remains virtually an incurable disease with a median overall survival (OS) of ∼3years and a 5-year survival of only ∼25% [2, 3]. The MBC Decade Report [2] shows that progress has been slow in terms of improved outcomes, quality of life (QoL), awareness and information regarding ABC. More recently, some studies seem to indicate an improvement in OS, mostly due to advances in human epidermal growth factor receptor 2 (HER2)-positive ABC [4–6].

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/annonc/mdy192

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Research works printed but not linked: 59

  1. Sundquist, 2017, Improved survival in metastatic breast cancer 1985–2016, Breast, 31, 46, 10.1016/j.breast.2016.10.005 · DOI · Paper page
  2. Malmgren, 2018, Differential presentation and survival of de novo and recurrent metastatic breast cancer over time: 1990–2010, Breast Cancer Res Treat, 167, 579, 10.1007/s10549-017-4529-5 · DOI
  3. Hölzel, 2017, Improved systemic treatment for early breast cancer improves cure rates, modifies metastatic pattern and shortens post-metastatic survival: 35-year results from the Munich Cancer Registry, J Cancer Res Clin Oncol, 143, 1701, 10.1007/s00432-017-2428-0 · DOI
  4. Cherny, 2017, ESMO-Magnitude of Clinical BenefitScale version 1.1, Ann Oncol, 28, 2340, 10.1093/annonc/mdx310 · DOI · Paper page
  5. Dykewicz, 2001, Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients, Clin Infect Dis, 33, 139, 10.1086/321805 · DOI · Paper page
  6. Noguchi, 2016, Phase 3, open-label, randomized study comparing 3-monthly with monthly goserelin in pre-menopausal women with estrogen receptor-positive advanced breast cancer, Breast Cancer, 23, 771, 10.1007/s12282-015-0637-4 · DOI
  7. Masuda, 2011, Monthly versus 3-monthly goserelin acetate treatment in pre-menopausal patients with estrogen receptor-positive early breast cancer, Breast Cancer Res Treat, 126, 443, 10.1007/s10549-010-1332-y · doi:10.1007/s10549-010-1332-y
  8. Tabernero, 2017, Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers, ESMO Open, 1, e000142, 10.1136/esmoopen-2016-000142 · doi:10.1136/esmoopen-2016-000142
  9. Cardoso, 2017, European Breast Cancer Conference manifesto on breast centres/units, Eur J Cancer, 72, 244, 10.1016/j.ejca.2016.10.023 · DOI
  10. Peccatori, 2013, Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, 24, vi160, 10.1093/annonc/mdt199 · DOI · Paper page
  11. Ethics Committee of American Society for Reproductive Medicine, 2013, Fertility preservation and reproduction in patients facing gonadotoxic therapies: a committee opinion, Fertil Steril, 100, 1224, 10.1016/j.fertnstert.2013.08.041 · DOI · Paper page
  12. Loren, 2013, Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update, J Clin Oncol, 31, 2500, 10.1200/JCO.2013.49.2678 · DOI · Paper page
  13. Walsh, 2017, Oncofertility: fertile ground for conflict between patient autonomy and medical values, Oncologist, 22, 860, 10.1634/theoncologist.2016-0373 · doi:10.1634/theoncologist.2016-0373
  14. Cardoso, 2017, Why are guidelines not followed in clinical practice?, Breast, 32, 245, 10.1016/j.breast.2016.12.004 · DOI
  15. Cardoso, 2012, 1st International consensus guidelines for advanced breast cancer (ABC1), Breast, 21, 242, 10.1016/j.breast.2012.03.003 · DOI · Paper page
  16. Robertson, 2016, Fulvestrant 500mg versus anastrozole 1mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial, Lancet, 388, 2997, 10.1016/S0140-6736(16)32389-3 · DOI · Paper page
  17. Hortobagyi, 2017, Updated results from MONALEESA-2, a phase 3 trial of first-line ribociclib + letrozole in hormone receptor-positive (HR+), HER2-negative (HER2–), advanced breast cancer (ABC), J Clin Oncol, 35, 1038, 10.1200/JCO.2017.35.15_suppl.1038 · DOI
  18. Tripathy, 2018, First-line ribociclib vs placebo with goserelin and tamoxifen or a non-steroidal aromatase inhibitor in premenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the randomized phase III MONALEESA-7 trial, Cancer Res, 78
  19. Di Leo, 2017, 236O_PR. MONARCH 3: abemaciclib as initial therapy for patients with HR+/HER2- advanced breast cancer, Ann Oncol, 28, mdx440.008
  20. Goetz, 2015, MONARCH 3: a randomized phase III study of anastrozole or letrozole plus abemaciclib, a CDK4/6 inhibitor, or placebo in first-line treatment of women with HR+, HER2-locoregionally recurrent or metastatic breast cancer (MBC), J Clin Oncol, 33, TPS624, 10.1200/jco.2015.33.15_suppl.tps624 · DOI
  21. Rugo, 2018, Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial, Ann Oncol, 29, 888, 10.1093/annonc/mdy012 · DOI
  22. Verma, 2017, Health-related quality of life (HRQoL) of postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) treated with ribociclib + letrozole: results from MONALEESA-2, J Clin Oncol, 35, 1020, 10.1200/JCO.2017.35.15_suppl.1020 · DOI
  23. Harbeck, 2017, Impact of disease progression status on time to deterioration of patient reported health related quality of life in first-line ER+, HER2–advanced/metastatic breast cancer patients in the PALOMA-2 study, Breast, 36, S43, 10.1016/S0960-9776(17)30684-7 · DOI
  24. Cristofanilli, 2016, Lancet Oncol, 17, 425, 10.1016/S1470-2045(15)00613-0 · DOI · Paper page
  25. Harbeck, 2016, Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial, Ann Oncol, 27, 1047, 10.1093/annonc/mdw139 · DOI
  26. Verma, 2016, Palbociclib in combination with fulvestrant in women with hormone receptor-positive/HER2-negative advanced breast cancer: detailed safety analysis from a multicenter, randomized, placebo-controlled, phase III study (PALOMA-3), Oncologist, 21, 1165, 10.1634/theoncologist.2016-0097 · DOI
  27. Dickler, 2017, MONARCH 1, a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR+/HER2- metastatic breast cancer, Clin Cancer Res, 23, 5218, 10.1158/1078-0432.CCR-17-0754 · DOI · Paper page
  28. Rugo, 2017, Abstract P6-11-12: subgroup analysis by prior treatment and disease burden in MONARCH 1: a phase 2 study of monotherapy abemaciclib, a CDK4 & 6 inhibitor, in patients with HR+/HER2- metastatic breast cancer (MBC) following chemotherapy, Cancer Res, 77, 11
  29. Tolaney, 2017, Abemaciclib for the treatment of brain metastases (BM) secondary to hormone receptor positive (HR+), HER2 negative breast cancer, J Clin Oncol, 35, 1019, 10.1200/JCO.2017.35.15_suppl.1019 · DOI
  30. Bachelot, 2012, Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study, J Clin Oncol, 30, 2718, 10.1200/JCO.2011.39.0708 · DOI · Paper page
  31. Royce, 2018, Everolimus plus endocrine therapy in the first- and second-line setting for postmenopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (BOLERO-4): an open-label, single-arm, phase 2 trial, JAMA Oncol, 10.1001/jamaoncol.2018.0060 · DOI
  32. Pritchard, 2013, Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2, Clin Breast Cancer, 13, 421, 10.1016/j.clbc.2013.08.011 · DOI
  33. Gradishar, 2017, Phase III study of lapatinib (L) plus trastuzumab (T) and aromatase inhibitor (AI) vs T+AI vs L+AI in postmenopausal women (PMW) with HER2+, HR+ metastatic breast cancer (MBC): ALTERNATIVE, J Clin Oncol, 35, 1004, 10.1200/JCO.2017.35.15_suppl.1004 · doi:10.1200/jco.2017.35.15_suppl.1004
  34. Gucalp, 2013, Phase II trial of bicalutamide in patients with androgen receptor–positive, estrogen receptor-negative metastatic breast cancer, Clin Cancer Res, 19, 5505, 10.1158/1078-0432.CCR-12-3327 · DOI · Paper page
  35. Bonnefoi, 2016, A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1), Ann Oncol, 27, 812, 10.1093/annonc/mdw067 · DOI · Paper page
  36. Traina, 2018, Enzalutamide for the treatment of androgen receptor-expressing triple-negative breast cancer, J Clin Oncol, 36, 884, 10.1200/JCO.2016.71.3495 · DOI · Paper page
  37. Paluch-Shimon, 2016, Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening, Ann Oncol, 27, v103, 10.1093/annonc/mdw327 · DOI · Paper page
  38. Paterson, 2017, Genetic testing in women with breast cancer: implications for treatment, Expert Rev Anticancer Ther, 17, 991, 10.1080/14737140.2017.1374175 · DOI
  39. Valencia, 2017, The role of genetic testing in patients with breast cancer: a review, JAMA Surg, 152, 589, 10.1001/jamasurg.2017.0552 · doi:10.1001/jamasurg.2017.0552
  40. Robson, 2017, Olaparib for metastatic breast cancer in patients with a germline BRCA mutation, N Engl J Med, 377, 523, 10.1056/NEJMoa1706450 · DOI · Paper page
  41. Litton, 2015, A phase 3, open-label, randomized, parallel, 2-arm international study of the oral PARP inhibitor talazoparib (BMN 673) in BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA), J Clin Oncol, 33, TPS1107, 10.1200/jco.2015.33.15_suppl.tps1107 · doi:10.1200/jco.2015.33.15_suppl.tps1107
  42. André, 2014, Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER), Lancet Oncol, 15, 267, 10.1016/S1470-2045(13)70611-9 · DOI · Paper page
  43. Le Tourneau, 2015, Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial, Lancet Oncol, 16, 1324, 10.1016/S1470-2045(15)00188-6 · DOI · Paper page
  44. Levin, 2011, Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system, Int J Radiat Oncol Biol Phys, 79, 1487, 10.1016/j.ijrobp.2009.12.061 · DOI · Paper page
  45. Torcuator, 2009, Initial experience with bevacizumab treatment for biopsy confirmed cerebral radiation necrosis, J Neurooncol, 94, 63, 10.1007/s11060-009-9801-z · DOI
  46. Boothe, 2013, Bevacizumab as a treatment for radiation necrosis of brain metastases post stereotactic radiosurgery, Neuro Oncol, 15, 1257, 10.1093/neuonc/not085 · doi:10.1093/neuonc/not085
  47. Wang, 2012, Reversal of cerebral radiation necrosis with bevacizumab treatment in 17 Chinese patients, Eur J Med Res, 17, 25., 10.1186/2047-783X-17-25 · DOI
  48. Tye, 2014, An analysis of radiation necrosis of the central nervous system treated with bevacizumab, J Neurooncol, 117, 321, 10.1007/s11060-014-1391-8 · DOI
  49. Delishaj, 2017, Bevacizumab for the treatment of radiation-induced cerebral necrosis: a systematic review of the literature, J Clin Med Res, 9, 273, 10.14740/jocmr2936e · DOI
  50. Bollet, 2012, Preoperative radio-chemotherapy in early breast cancer patients: long-term results of a phase II trial, Radiother Oncol, 102, 82, 10.1016/j.radonc.2011.08.017 · doi:10.1016/j.radonc.2011.08.017
  51. Coles, 2017, Preoperative radiation therapy: the ‘new’ targeted breast cancer treatment?, Eur J Cancer, 78, 116, 10.1016/j.ejca.2017.03.027 · doi:10.1016/j.ejca.2017.03.027
  52. Roila, 2016, MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients, Ann Oncol, 27, v119, 10.1093/annonc/mdw270 · DOI · Paper page
  53. Rugo, 2017, Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial, Lancet Oncol, 18, 654, 10.1016/S1470-2045(17)30109-2 · DOI
  54. Bun, 2018, Symptom management: the utility of regional cooling for hand-foot syndrome induced by pegylated liposomal doxorubicin in ovarian cancer, Support Care Cancer, 26, 2161, 10.1007/s00520-018-4054-z · doi:10.1007/s00520-018-4054-z
  55. Gomez, 2011, Clinical presentation and management of hand–foot skin reaction associated with sorafenib in combination with cytotoxic chemotherapy: experience in breast cancer, Oncologist, 16, 1508, 10.1634/theoncologist.2011-0115 · DOI
  56. Witt, 2016, Complementary and integrative medicine for breast cancer patients - evidence based practical recommendations, Breast, 28, 37, 10.1016/j.breast.2016.04.012 · DOI
  57. Witt, 2017, A comprehensive definition for integrative oncology, J Natl Cancer Inst Monogr, 2017, 3
  58. Oliveira, 2017, OR135—effect of exercise on cardiovascular fitness and quality of life outcomes in advanced breast cancer patients, Breast, 36, S71, 10.1016/S0960-9776(17)30754-3 · doi:10.1016/s0960-9776(17)30754-3
  59. Liedtke, 2017, AGO recommendations for the diagnosis and treatment of patients with early breast cancer: update 2017, Breast Care (Basel), 12, 172, 10.1159/000477575 · doi:10.1159/000477575

Cited by

See all 1,171

Metadata

Authors
Cardoso, F., Senkus, E., Costa, A., Papadopoulos, E., Aapro, M., André, F., Harbeck, N., Aguilar Lopez, B., Barrios, C. H., Bergh, J., Biganzoli, L., Boers-Doets, C. B., Cardoso, M. J., Carey, L. A., Cortés, J., Curigliano, G., Diéras, V., El Saghir, N. S., Eniu, A., Fallowfield, L., Francis, P. A., Gelmon, K., Johnston, S. R. D., Kaufman, B., Koppikar, S., Krop, I. E., Mayer, M., Nakigudde, G., Offersen, B. V., Ohno, S., Pagani, O., Paluch-Shimon, S., Penault-Llorca, F., Prat, A., Rugo, H. S., Sledge, G. W., Spence, D., Thomssen, C., Vorobiof, D. A., Xu, B., Norton, L., & Winer, E. P.
Venue
Annals of Oncology
Publisher
Elsevier BV
Published
2018-08
Volume
29
Issue
8
Pages
1634-1657
ISSN
0923-7534 (ISSN-L)
DOI
10.1093/annonc/mdy192
OpenAlex
W4239051461
Cited by
1,171
References
12
FWCI
48.09
Type
journal article
Language
en
Open access
hybrid
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4). https://app.cochat.ai/papers/10.1093/annonc/mdy192
The paper
Cardoso, F., Senkus, E., Costa, A., Papadopoulos, E., Aapro, M., André, F., Harbeck, N., Aguilar Lopez, B., Barrios, C. H., Bergh, J., Biganzoli, L., Boers-Doets, C. B., Cardoso, M. J., Carey, L. A., Cortés, J., Curigliano, G., Diéras, V., El Saghir, N. S., Eniu, A., . . . Winer, E. P. (2018). 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4). Annals of Oncology. https://doi.org/10.1093/annonc/mdy192

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.